Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High – Should You Buy?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $28.08 and last traded at $27.9030, with a volume of 683207 shares trading hands. The stock had previously closed at $27.76.

Analyst Ratings Changes

ROIV has been the subject of several recent research reports. Guggenheim raised their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. The Goldman Sachs Group increased their price objective on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Leerink Partners boosted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. HC Wainwright raised their price target on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Finally, Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Stock Down 0.4%

The business’s fifty day moving average is $23.44 and its 200-day moving average is $19.07. The stock has a market capitalization of $19.78 billion, a PE ratio of -23.59 and a beta of 1.22.

Insiders Place Their Bets

In other news, insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total value of $22,122,381.45. Following the transaction, the insider directly owned 20,267,429 shares in the company, valued at $440,005,883.59. This trade represents a 4.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew Gline sold 1,740,000 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $21.68, for a total value of $37,723,200.00. Following the sale, the chief executive officer owned 17,290,820 shares of the company’s stock, valued at $374,864,977.60. The trade was a 9.14% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 13,318,014 shares of company stock worth $315,727,023. Corporate insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund boosted its position in Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares during the last quarter. Bank of Montreal Can increased its holdings in Roivant Sciences by 1.3% in the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after buying an additional 516 shares during the last quarter. Bessemer Group Inc. raised its stake in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Allworth Financial LP grew its position in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in shares of Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after acquiring an additional 588 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.